A Phase II Randomized, Blinded, and Placebo-controlled Trial of CMV RNA-Pulsed Dendritic Cells With Tetanus-Diphtheria Toxoid Vaccine in Patients With Newly-Diagnosed Glioblastoma
Phase of Trial: Phase II
Latest Information Update: 30 Jul 2018
At a glance
- Drugs Cancer vaccine-pp65 (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- Acronyms ATTAC-II
- 21 Mar 2018 Planned number of patients changed from 75 to 150.
- 22 Feb 2018 Planned number of patients changed from 150 to 75.
- 13 Oct 2017 New trial record